Comparison of apalcillin (4g/day) and carbenicillin (4g/day) in respiratory tract innfection

Kenzo Shiota, Fumio Miki, Kenji Kubo, Masakazu Kohno, Kenji Takamatsu, Keizo Beppu, Yasumichi Kato, Akira Saito, Ichiro Nakayama, Mikihiko Tango, Tsuyoshi Atsumi, Akira Ujiie, Yasukuni Abe, Osamu Yajima, Masumi Tomizawa, Yoshio Kinoshita, Fumio Nagahama, Takehito Nakabayashi, Hiroshi Kon, Toshio KirisawaNorimichi Konno, Masatsugu Abe, Yoshisuke Iwata, Yoshinori Ohtsuka, Ryoji Ohashi, Jutaro Shimomura, Satoshi Yaguchi, Hiroaki Hiraga, Tokio Wakamatsu, Yoko Moriyama, Kiyoshi Konno, Kotaro Oizumi, Izumi Hayashi, Akira Watanabe, Hajimu Takeda, Masanaga Takato, Shiro Kawashima, Osamu Sekine, Nobuki Aoki, Yoshimaru Usuda, Yasuko Yuasa, Fusanosuke Yamasaku, Yasutoshi Suzuki, Masataka Katsu, Kunio Imataka, Hiroharu Ogihara, Akio Aoyagi, Fuyuhiko Higashi, Hisashi Takizuka, Masato Nakano, Kenichi Okayama, Shinji Okui, Mieko Kawai, Masanori Adachi, Reiko Kanzaki, Keimei Mashimo, Yoshiji Yamane, Sumio Yamaoka, Shiro Miwa, Otohiko Kunii, Kazufuto Fukaya, Yasushi Ueda, Fumio Matsumoto, Atsushi Saito, Jingoro Shimada, Masahisa Ohmori, Kohya Shiba, Takehisa Yamaji, Hironobu Ihara, Toshio Hojo, Tadashi Miyahara, Keiichi Nakagawa, Kentaro Watanabe, Hirosuke Nakazawa, Toshio Kihara, Tatsuo Suzuki, Junzaburo Kabe, Hiroyoshi Ishibashi, Kaoru Shimada, Takashi Inamatsu, Hiroichi Tanimoto, Akio Tachibana, Kanzo Suzuki, Osamu Kitamoto, Hiroyuki Kobayashi, Hideo Ikemoto, Kazuyoshi Watanabe, Junko Hibino, Kohkichi Fukushima, Akira Itoh, Kunihiko Shindo, Jun Senba, Kou Murohashi, Shohei Nagaoka, Shigeki Odagiri, Takashi Suyama, Makio Kurihara, Hideyuki Hasegawa, Ippei Fujimori, Shoichiro Irimajiri, Yoshio Kobayashi, Michinori Kohno, Kaoru Ohyama, Kuniyoshi Suzuki, Toshiyuki Yamamoto, Masahito Kato, Hirohiko Nagasaka, Kozo Mori, Toshihiko Takeuchi, Saburo Kitamura, Kunio Nanjo, Joichi Kato, Nobuo Maekawa, Mighiyasu Nakanishi, Mitsuru Kawai, Takuya Kurasawa, Norio Inaba, Yoshiro Oda, Takekuni Iwata, Hiroshi Okubo, Yuruko Okamoto, Fumihiko Uba, Yoshihiro Ueda, Keigo Maehara, Seibun Yonezu, Kanshi Mase, Takehiro Tsujimoto, Kenichi Shimizu, Eiro Tsubura, Yoshihiro Takishita, Shigeharu Morioka, Rinzo Soejima, Yoshihito Niki, Osamu Kato, Chiaki Fujii, Takeshi Kikuchi, Yoshiro Sawae, Kaoru Okada, Kohei Hara, Masao Nakatomi, Kinichi Izumikawa, Tsuneo Tsutsumi, Akira Ikebe, Keizo Yamaguchi, Koichi Watanabe, Keizo Matsumoto, Yoshio Uzuka, Masato Hayashi, Ryokichi Takasugi, Hiroshi Nishimura

    研究成果: Article査読

    抄録

    The therapeutic efficacy and safety of apalcillin (APPC) were objectively compared with those of carbenicillin (CBPC) in patients with acute or chronic respiratory tract infections in the well controlled study at 30 institutions in Japan. One hundred eighty seven patients were given daily 4g of APPC or CBPC in 2 divided doses by intravenous drip-infusion for, in principle, 14 days. The therapeutic effects were analyzed statistically in 159 patients (79 administered APPC, 80 administered CBPC) after excluding those in whom the initial suspicion of infection was not confirmed or the medication was not performed in accordance with the rule of protocol. The adverse reactions were also analyzed statistically in 182 patients (APPC 93; CBPC 89) in whom the judgement was possible. The results obtained were as follows: 1) Significantly more patients in the APPC group had highly eleveted body temperature than that in the CBPC group, on the other hand, significantly more patients in the CBPC group had severe infection than that in the APPC group. However, there was no other significant intergroup difference in the background factors of the patients. 2) In total 159 patients therapeutic effects of APPC (83.5% for good to excellent response) was significantly superior to that of CBPC (55.0% for good to excellent response) (P∨0.001). Efficacy rate in the patients treated with APPC was also significantly higher than that with CBPC in the group of chronic respiratory tract infections. When patients were classified into three groups (severe, moderate and mild) with respect to severity, statistically significant differences in clinical efficacy were observed in the moderate or mild cases (APPC>CBPC) while no difference was observed in the severe cases. 3) No significant difference was observed between the two drug groups in bacteriological efficacy against causative organisms isolated from patients. 4) The improvement of fever, volume of sputum and erythrocytes sedimentation rate was significantly better in the APPC group than in the CBPC group. 5) Significantly more patients in the CBPC group had elevated blood urea nitrogen after treatment than that in the APPC group. However, there was no other significant intergroup difference in incidence of adverse reactions. 6) From these comparative results on therapeutic effects and side effects of these two drugs, it is thought that APPC is more useful than CBPC in the treatment of chronic respiratory infections.

    本文言語English
    ページ(範囲)1223-1277
    ページ数55
    ジャーナルChemotherapy
    29
    11
    DOI
    出版ステータスPublished - 1981

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    フィンガープリント 「Comparison of apalcillin (4g/day) and carbenicillin (4g/day) in respiratory tract innfection」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル